MCIA
BMRN icon

Mountain Capital Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mountain Capital Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200
Closed -$19K – 86
2017
Q3 		$19K Hold
200
– – 0.02% 188
2017
Q2 		$18K Buy
+200
New +$18.2K 0.02% 223

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mountain Capital Investment Advisors's BMRN Position: Q4 2017 in Review

Mountain Capital Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 200 shares — an estimated $19K sold.

Mountain Capital Investment Advisors first reported a position in BMRN in Q2 2017 and held it in 2 quarters. The position peaked at $19K in Q3 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

  • Mountain Capital Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Mountain Capital Investment Advisors sold 200 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $19K.
  • Mountain Capital Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Mountain Capital Investment Advisors's BioMarin Pharmaceuticals position peaked at $19K in Q3 2017.
  • 438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Mountain Capital Investment Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.